trending Market Intelligence /marketintelligence/en/news-insights/trending/MKU6FOBebd_813xhv0xCrg2 content esgSubNav
In This List

Relmada Therapeutics raises $115M from stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Relmada Therapeutics raises $115M from stock offering

Relmada Therapeutics Inc. raised $115 million from a public offering of shares after underwriters exercised an option to buy additional stock.

The New York-based pharmaceutical company offered 3,833,334 shares at $30 apiece, including 500,000 shares as part of underwriters' overallotment option.

Relmada intends to use the gross proceeds from the offering to fund the research and development of its treatment-resistant depression drug REL-1017, or dextromethadone, and for general corporate purposes.

Jefferies, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the offering.